SYNERGIST SERVICES

Their core work

Synergist Services is a Brussels-based consultancy that provides specialized support services to large European health research consortia, particularly in pharmacovigilance, patient engagement, and medication safety. They operate exclusively as a third-party contributor — brought in by consortium partners for specific expertise rather than participating directly as a beneficiary. Their work spans medication safety monitoring in pregnancy, patient involvement in drug development, cohort study harmonization, and digital health information platforms. The consistent third-party role across all five projects suggests they offer niche professional services (likely regulatory, data management, or patient engagement consulting) that multiple health consortia need but don't build in-house.

What they specialise in

How they've shifted over time

With all projects starting between 2018 and 2020, Synergist Services has a compact H2020 track record that makes long-term evolution difficult to trace. However, a clear pattern emerges: early entries (SHARE4RARE, PARADIGM) focused on patient engagement and participation frameworks, while later projects (ConcePTION, Gravitate-Health) shifted toward concrete medication safety systems — pharmacovigilance in pregnancy, adherence monitoring, and risk minimisation tools. This suggests a maturation from broad patient-involvement consulting toward specialized pharmaceutical safety services.

Moving from general patient engagement consulting toward specialized pharmaceutical safety and medication management services, likely positioning for post-H2020 pharmacovigilance work.

How they like to work

Synergist Services operates exclusively as a third-party contributor, never leading or directly participating as a named beneficiary. This is a distinctive pattern — they are brought in by consortium members who need their specific capabilities, indicating they are a trusted specialist that multiple organizations call upon. With 141 unique partners across 27 countries from just 5 projects, they integrate into very large consortia (typically IMI and major RIA projects with 30+ partners), functioning as a flexible service provider rather than a core research partner.

Despite only 5 projects, their third-party role in large IMI-scale consortia gives them indirect connections to 141 unique partners across 27 countries — an unusually broad network for a small company, concentrated in Western European pharmaceutical and public health research.

What sets them apart

Synergist Services occupies a rare niche: a Brussels-based SME that health research consortia repeatedly bring in as a third party for specialized support. Their exclusive third-party status across all projects suggests they provide a very specific service — likely regulatory consulting, patient engagement facilitation, or data management — that is valuable enough for multiple independent consortia to contract. For consortium builders, they represent low-risk, flexible expertise that can be added without consuming beneficiary slots.

Highlights from their portfolio

• ConcePTION
  Major IMI2 initiative building a Europe-wide ecosystem for monitoring medication safety in pregnancy, running until 2024 — their longest and most specialized engagement.
• Gravitate-Health
  Large-scale project running until 2026 focused on personalized medication information, representing their most recent and forward-looking involvement.
• PARADIGM
  IMI2 project that set European frameworks for meaningful patient engagement in drug development — influential in shaping regulatory practice.